EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CERSI‑AT: practical guidance for decentralized manufacturing

Centre of Excellence in Regulatory Science and Innovation for Advanced Therapies

Cell and Gene Therapy Insights · 09.06.2026 · 12 (4) · 423–445

DOI: 10.18609/cgti.2026.047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 09.06.2026. Verfasst von Centre of Excellence in Regulatory Science and Innovation for Advanced Therapies. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CERSI-AT, coordinated by the Cell and Gene Therapy Catapult, advances regulatory science to strengthen decision-making for ATMPs. Through structured stakeholder engagement, pilot projects, and targeted outputs, including white papers and regulatory briefings, it aims to streamline ATMP pathways and position the UK as a global leader in advanced therapy innovation. Decentralized manufacturing (DM) is emerging with its potential to enable timely access of medicines, including advanced therapy medicinal products (ATMPs), which have with a very short shelf life or are very personalized to the recipient. In 2025, the UK introduced a regulatory framework that permits DM via Modular Manufacture (MM) or Point of Care (POC) pathways. In this article, CERSI-AT has created practical guidance for developers planning DM in the UK. Illustrative examples deliberately extend beyond formal Medicines and Healthcare products Regulatory Agency (MHRA) guidance to stimulate strategy development and implementation planning. Key technical, operational, and regulatory challenges associated with implementing DM across distributed sites are examined, including maintaining consistent quality, ensuring robust supply chains, achieving process comparability, and coordinating quality systems. Mitigation strategies are proposed, grounded in risk-based control, standardization, digital integration, and enhanced process understanding, alongside the importance of early regulatory engagement and lifecycle planning. Additionally, critical regulatory components are described, such as the DM designation process, Good Manufacturing Practice considerations, and the role of the Decentralised Manufacturing Master File (DMMF) in supporting oversight and compliance.

Zitieren

APA

Therapies, C. O. E. I. R. S. A. I. F. A. (2026). CERSI‑AT: practical guidance for decentralized manufacturing. Cell and Gene Therapy Insights, 12(4), 423–445. https://doi.org/10.18609/cgti.2026.047

Vancouver

Therapies COEIRSAIFA. CERSI‑AT: practical guidance for decentralized manufacturing. Cell and Gene Therapy Insights. 2026;12(4):423–445. doi:10.18609/cgti.2026.047

BibTeX
@article{Therapies2026,
  author = {Therapies, Centre of Excellence in Regulatory Science and Innovation for Advanced},
  title = {CERSI‑AT: practical guidance for decentralized manufacturing},
  journal = {Cell and Gene Therapy Insights},
  year = {2026},
  volume = {12},
  number = {4},
  pages = {423–445},
  doi = {10.18609/cgti.2026.047}
}
Kostenlos starten →